Prognostic factors in Hodgkin lymphoma
PJ Broeckelmann, MK Angelopoulou… - Seminars in …, 2016 - Elsevier
During the last decades, the prognosis of Hodgkin lymphoma (HL) has been improved
significantly with the introduction of effective chemotherapy and the implementation of risk …
significantly with the introduction of effective chemotherapy and the implementation of risk …
Long‐term outcomes among 2‐year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b‐cell lymphoma
BACKGROUND Autologous hematopoietic cell transplantation (auto‐HCT) is a standard
therapy for relapsed classic Hodgkin lymphoma (cHL) and diffuse large B‐cell lymphoma …
therapy for relapsed classic Hodgkin lymphoma (cHL) and diffuse large B‐cell lymphoma …
Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis
R Dada, J Zekri, R Al Saadi - Expert opinion on biological therapy, 2016 - Taylor & Francis
Objectives: This meta-analysis evaluated the effect of single agent brentuximab vedotin (BV)
in patients with relapsed/refractory Hodgkin lymphoma (HL). Patients and methods: A …
in patients with relapsed/refractory Hodgkin lymphoma (HL). Patients and methods: A …
LACE versus BEAM conditioning in relapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy
N Khattry, A Gupta, R Jain, A Gore… - International journal of …, 2016 - Springer
We compared the lomustine, cytarabine, cyclophosphamide and etoposide (LACE) and
BCNU, etoposide, cytarabine, melphalan (BEAM) conditioning regimens for toxicity …
BCNU, etoposide, cytarabine, melphalan (BEAM) conditioning regimens for toxicity …
[HTML][HTML] Chidamide and decitabine can synergistically induce apoptosis of Hodgkin lymphoma cells by up-regulating the expression of PU. 1 and KLF4
T Jiang, F Wang, L Hu, X Cheng, Y Zheng, T Liu, Y Jia - Oncotarget, 2017 - ncbi.nlm.nih.gov
Epigenetic abnormalities play important roles in the pathogenesis of Hodgkin lymphoma
(HL). Highly expressed class I histone acetyltransferase (HDAC) and hyper-methylation of …
(HL). Highly expressed class I histone acetyltransferase (HDAC) and hyper-methylation of …
Morbidity burden in survivors of multiple myeloma who underwent autologous transplantation: A Bone Marrow Transplantation Survivor Study
M Arora, Y Chen, L Hageman, J Wu, W Landier… - Cancer, 2020 - Wiley Online Library
Background Autologous blood or bone marrow transplantation (aBMT) is considered the
standard of care for patients with multiple myeloma (MM). Significantly improved survival …
standard of care for patients with multiple myeloma (MM). Significantly improved survival …
Relapsed/refractory Hodgkin lymphoma: what is the best salvage therapy and do we need RIC-alloSCT?
M Hertzberg - Hematology/Oncology Clinics, 2014 - hemonc.theclinics.com
Relapsed/Refractory Hodgkin Lymphoma - Hematology/Oncology Clinics Skip to Main
Content Advertisement Hematology/Oncology Clinics Log in Register Log in Subscribe Claim …
Content Advertisement Hematology/Oncology Clinics Log in Register Log in Subscribe Claim …
Modified BEAM as conditioning regimen for lymphoma patients undergoing autologous hematopoietic stem cell transplantation
P Galieni, E Troiani, C Bigazzi, S Mazzotta… - Bone Marrow …, 2018 - nature.com
Over the last 30 years, BEAM has been the most widely used conditioning regimen before
autologous hematopoietic stem cell transplantation (auto-HSCT) for patients with Hodgkin …
autologous hematopoietic stem cell transplantation (auto-HSCT) for patients with Hodgkin …
[HTML][HTML] Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma …
KB Smeland, CE Kiserud, GF Lauritzsen… - …, 2015 - ncbi.nlm.nih.gov
The prognosis for patients with Hodgkin lymphoma (HL) under 60-65 years is very good,
with 5-year overall survival (OS) of 88%-95% with modern combined modality therapy, even …
with 5-year overall survival (OS) of 88%-95% with modern combined modality therapy, even …
Lomustine, cytarabine, cyclophosphamide, etoposide–An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or …
A Gupta, A Gokarn, D Rajamanickam… - Journal of Cancer …, 2018 - journals.lww.com
Background: High-dose chemotherapy followed by autologous hematopoietic stem cell
transplant (HSCT) is the treatment of choice for patients with relapsed and refractory (RR) …
transplant (HSCT) is the treatment of choice for patients with relapsed and refractory (RR) …